Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Computerized Thermal Imaging CIO (formerly COII) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (3655)	10/30/1999 6:14:00 PM
From: chirodoc	Read Replies (1) \| Respond to of 6039

bluediamond, regarding sensitivity sensitivity is for an adjunct device becuase it is designed to follow a mammogram and find the malignancies among all the false positives. this is where cti is 96% sensitive (accurate). specificity means that it picks up lots of positives (often false) much like a mammogram. the cti machine will be tested as a screening device (like a mammogram)once we are approved as an adjunct. rumor has it that by slightly tweaking the system it can be switched from being a SENSITIVE to a SPECIFIC device and used for generalized screening. this could require many more clinical patients than the adjunctive trials. my assumption is that a woman could eventually have two cti scans, one specific (as a general scan) and then follow this with a "sensitive" scan (like the one going thru FDA trials now) to differentiate malignant from benign findings. i am not certain if it can be BOTH at the SAME time. curtis